Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 8/20 | 0.42 |
| ▸ | CA1 | P00915 | 8/20 | 0.42 |
| ▸ | CA2 | P00918 | 8/20 | 0.42 |
| ▸ | CA4 | P22748 | 8/20 | 0.42 |
| ▸ | CA9 | Q16790 | 8/20 | 0.42 |
| ▸ | FNTA | P49354 | 3/20 | 0.41 |
| ▸ | FNTB | P49356 | 3/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8272711 | 0.93 | PTGER2 (0.49) | NR1H2NR1H3PTGER2MEN1KMT2A | |
| SCHEMBL13399073 | 0.90 | PTGER2 (0.51) | NR1H2NR1H3PTGER2MEN1KMT2A | |
| SCHEMBL6058900 | 0.84 | MEN1 (0.47) | NR1H2NR1H3PTGER2MEN1KMT2A | |
| SCHEMBL5043195 | 0.83 | TLR7 (0.47) | NR1H2NR1H3PTGER2MEN1KMT2A | |
| SCHEMBL5048029 | 0.83 | FFAR1 (0.47) | NR1H2NR1H3PTGER2MEN1KMT2A | |
| SCHEMBL8211041 | 0.82 | CA12 (0.52) | NR1H2NR1H3PTGER2MEN1KMT2A | |
| SCHEMBL13399074 | 0.82 | CA12 (0.61) | PTGER2MEN1KMT2ACA12CA1 | |
| SCHEMBL13399264 | 0.81 | PTGER2 (0.64) | PTGER2CA12CA1CA2CA4 | |
| Hydrochloric Acid SCHEMBL5046437 | 0.81 | CA12 (0.51) | NR1H2NR1H3PTGER2MEN1KMT2A | |
| SCHEMBL6059327 | 0.80 | CA12 (0.51) | PTGER2MEN1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622475-B2 | EP2 agonists | PFIZER INC (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080045545-A1 | EP2 AGONISTS | PFIZER INC. | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045545-A1 | EP2 AGONISTS | PTGER2, PTGER1, PTGIR | NR1H2 179/4885NR1H3 234/4885PTGER2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.